Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2006

View Archived Issues

GRIMs: Novel cytokine-driven tumor suppressors

Anticoagulant proteins potentially useful for pneumonia and ARDS

Antigenics rounds up Q2 developments

Eisai reviews highlights of quarter

Antiallodynic effects of NAALADase inhibition in an in vivo model of neuropathic pain

IL-22: a novel target for autoimmune and inflammatory diseases

HIF-1alpha inhibition enhances antitumor activity of temozolomide

Oncolys BioPharma cleared to begin U.S. clinical trials of telomelysin

U. of Pittsburgh awarded NIAID grant for avian flu vaccine

Antisoma to study AS-1409 in renal cancer and melanoma

Agreement to study AE-37 in prostate cancer in Europe

Pharmexa cleared to begin phase Ib study of HIV vaccine EP-1090

Enrollment open in pivotal study of pralatrexate for peripheral T-cell lymphoma

U.S. DHS certifies BioThrax as approved product for homeland security

Bionomics profiles lead programs

BioDiem signs CRADA with CDC to develop bird flu vaccine

Caprospinol shows favorable results in acute toxicity study

Recent Cardiome patent describes new treatment options for cardiovascular disease

Chrysalin fails to meet primary endpoint in fracture repair

New agents for treating respiratory disorders reported in recent patent literature

Novel treatment options for inflammatory disorders disclosed in recent patents

Recent Synta patent describes novel immunosuppressant agents

German approval for Foster in asthma

Zensana NDA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...